Reconstituted HDL nanoparticles were loaded with siRNAs against two key cancer genes and administered intravenously into orthotopic mouse models of cancer, and were able to effectively silence the expression of their targets.
The presentation will focus on data from an ongoing phase I study with Atu027 in subjects with advanced solid cancer. “Key findings presented will include safety, tolerability and pharmacokinetic data, as well as indications of anti-tumor activity,” Silence said.
The phase I drug, ALN-VSP02, comprises two siRNAs, one targeting vascular endothelial growth factor and one targeting kinesin spindle protein, both of which the firm said are critical for the growth and survival of cancer cells.
Prosecutors have charged a former Drexel University professor with theft for allegedly spending federal grant money on adult entertainment and other unrelated expenses, according to the Philadelphia Inquirer.